Pharmathene, Inc. (f/k/a PIP)

[cash2go]

Valortim trial at stage 2 exposure

African Green Monkey Model (human trials will not be done post stage 2 exposure)

6 AGMs were treated with one intravenous dose of 10 mg/kg Valortim® when positive by ECL; a second cohort of 6 AGMs was treated with 2 intravenous doses of 10 mg/kg Valortim® (the first given when positive by ECL and the second dose administered 24 hours later), and a third cohort of 6 AGMs was treated with one intravenous dose of 20 mg/kg Valortim® when positive by ECL.

Results showed that 56% (10 of 18) of the Valortim®-treated animals survived while all saline-treated controls (3) succumbed to inhalational anthrax on or before the fifth day post-exposure. Extended time-to-death (days 6-9) was observed in 5 of the 8 Valortim®-treated animals that succumbed to inhalational anthrax.

http://phx.corporate-ir.net/phoenix.zhtml?c=191999&p=irol-newsArticle&ID=1200718&highlight=

ONE DOSE Valortim, versus 60 days of IV antibiotic treatment now approved that results in 90% death for stage 2 patients.

Now you see why the DOD will continue funding Valortim trials.